Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CABA Cabaletta Bio	$1.51 +1.3%	$1.71	$0.99 ▼ $8.77	$75.61M	2.7	1.67 million shs	1.83 million shs
CLYM Climb Bio	$1.26	$1.25	$1.05 ▼ $9.21	$85.14M	-0.13	353,630 shs	262,575 shs
GBIO Generation Bio	$0.35 +6.9%	$0.38	$0.30 ▼ $3.65	$22.12M	2.59	398,252 shs	831,790 shs
MCRB Seres Therapeutics	$11.60 +6.9%	$8.34	$6.53 ▼ $30.60	$94.75M	2.75	132,566 shs	75,914 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CABA Cabaletta Bio	-7.22%	-1.97%	-39.92%	+43.27%	-78.87%
CLYM Climb Bio	-1.56%	+1.61%	-9.35%	+11.50%	+125,999,900.00%
GBIO Generation Bio	-5.17%	+3.09%	-24.31%	+1.85%	-84.72%
MCRB Seres Therapeutics	-4.45%	-2.34%	+31.83%	+4.31%	-33.19%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CABA Cabaletta Bio	1.5251 of 5 stars	3.5	2.0	0.0	0.0	0.8	0.6
CLYM Climb Bio	2.6372 of 5 stars	3.6	0.0	0.0	0.6	2.5	1.3
GBIO Generation Bio	2.9422 of 5 stars	3.5	3.0	0.0	0.0	3.3	1.3
MCRB Seres Therapeutics	3.5315 of 5 stars	2.9	2.0	4.6	2.8	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CABA Cabaletta Bio	3.00	Buy	$14.43	855.53% Upside
CLYM Climb Bio	3.25	Buy	$9.00	614.29% Upside
GBIO Generation Bio	3.00	Buy	$7.33	1,978.02% Upside
MCRB Seres Therapeutics	1.75	Reduce	$73.67	535.06% Upside

Current Analyst Ratings Breakdown

Latest GBIO, CLYM, CABA, and MCRB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	CABA Cabaletta Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/6/2025	CLYM Climb Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$10.00
5/22/2025	CLYM Climb Bio	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/22/2025	CLYM Climb Bio	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$7.00
5/16/2025	CABA Cabaletta Bio	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $13.00
5/15/2025	CABA Cabaletta Bio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$23.00 ➝ $25.00
5/8/2025	GBIO Generation Bio	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
5/8/2025	MCRB Seres Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$1.25 ➝ $6.00
4/10/2025	GBIO Generation Bio	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00

(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	$3.12 per share	N/A
CLYM Climb Bio	N/A	N/A	N/A	N/A	$3.15 per share	N/A
GBIO Generation Bio	$19.89M	1.19	N/A	N/A	$1.29 per share	0.27
MCRB Seres Therapeutics	$126.32M	0.80	N/A	N/A	$1.61 per share	7.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CABA Cabaletta Bio	-$115.86M	-$2.54	0.00	N/A	N/A	N/A	-78.29%	-65.68%	8/6/2025 (Estimated)
CLYM Climb Bio	-$73.90M	-$2.38	0.00	N/A	N/A	N/A	-43.95%	-42.94%	8/13/2025 (Estimated)
GBIO Generation Bio	-$131.67M	-$1.08	0.00	N/A	N/A	-292.92%	-75.84%	-30.40%	8/6/2025 (Estimated)
MCRB Seres Therapeutics	$140K	-$4.60	N/A	N/A	N/A	N/A	-41,084.76%	-55.87%	8/12/2025 (Estimated)

Latest GBIO, CLYM, CABA, and MCRB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	CABA Cabaletta Bio	-$0.67	-$0.71	-$0.04	-$0.71	N/A	N/A
5/14/2025	Q1 2025	CLYM Climb Bio	-$0.15	-$0.31	-$0.16	-$0.31	N/A	N/A
5/7/2025	Q1 2025	GBIO Generation Bio	-$0.25	-$0.22	+$0.03	-$0.22	$1.70 million	$8.72 million
5/7/2025	Q1 2025	MCRB Seres Therapeutics	-$0.67	-$2.24	-$1.57	$3.75	$10.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	N/A
CLYM Climb Bio	N/A	N/A	N/A	N/A	N/A
GBIO Generation Bio	N/A	N/A	N/A	N/A	N/A
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CABA Cabaletta Bio	N/A	3.96	3.96
CLYM Climb Bio	N/A	14.25	14.25
GBIO Generation Bio	N/A	8.43	8.43
MCRB Seres Therapeutics	N/A	2.11	2.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CABA Cabaletta Bio	N/A
CLYM Climb Bio	69.76%
GBIO Generation Bio	95.22%
MCRB Seres Therapeutics	59.34%

Insider Ownership

Company	Insider Ownership
CABA Cabaletta Bio	11.25%
CLYM Climb Bio	3.20%
GBIO Generation Bio	21.10%
MCRB Seres Therapeutics	4.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CABA Cabaletta Bio	50	50.74 million	45.03 million	Optionable
CLYM Climb Bio	9	67.58 million	65.41 million	N/A
GBIO Generation Bio	150	67.04 million	52.89 million	Optionable
MCRB Seres Therapeutics	330	8.73 million	8.32 million	Optionable

GBIO, CLYM, CABA, and MCRB Headlines

Recent News About These Companies

Seres Therapeutics (NASDAQ:MCRB) Shares Cross Above Fifty Day Moving Average - What's Next?

July 5 at 4:47 AM | marketbeat.com

Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting

May 27, 2025 | globenewswire.com

Seres Therapeutics (MCRB) Upgraded to Buy: What Does It Mean for the Stock?

May 23, 2025 | zacks.com

Wall Street Analysts Believe Seres Therapeutics (MCRB) Could Rally 713.09%: Here's is How to Trade

May 16, 2025 | zacks.com

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2025 Earnings Call Transcript

May 9, 2025 | insidermonkey.com

Chardan Capital Downgrades Seres Therapeutics (MCRB)

May 9, 2025 | msn.com

Seres Therapeutics, Inc. (MCRB) Q1 2025 Earnings Call Transcript

May 7, 2025 | seekingalpha.com

Seres Therapeutics reports Q1 EPS $3.75, consensus $1.97

May 7, 2025 | msn.com

Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

May 7, 2025 | globenewswire.com

Seres Therapeutics Q1 2025 Earnings Preview

May 6, 2025 | msn.com

Why Seres Therapeutics, Inc.’s (MCRB) Stock Is Down 5.09%

May 6, 2025 | aaii.comA

Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases

April 29, 2025 | globenewswire.com

Petri Dish: Boston Scientific CFO retires; Biotech undergoes 1-for-20 reverse stock split

April 24, 2025 | bizjournals.com

Seres Therapeutics trading resumes

April 24, 2025 | markets.businessinsider.com

Seres Therapeutics trading halted, volatility trading pause

April 24, 2025 | markets.businessinsider.com

Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025

April 23, 2025 | globenewswire.com

Seres Therapeutics trading halted, news pending

April 22, 2025 | markets.businessinsider.com

Why Seres Therapeutics, Inc.’s (MCRB) Stock Is Up 10.81%

April 21, 2025 | aaii.comA

Down -48.7% in 4 Weeks, Here's Why Seres Therapeutics (MCRB) Looks Ripe for a Turnaround

April 17, 2025 | zacks.com

Why Seres Therapeutics, Inc.’s (MCRB) Stock Is Up 7.28%

April 14, 2025 | aaii.comA

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2024 Earnings Call Transcript

March 14, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GBIO, CLYM, CABA, and MCRB Company Descriptions

Cabaletta Bio NASDAQ:CABA

$1.51 +0.02 (+1.34%)

Closing price 04:00 PM Eastern

Extended Trading

$1.52 +0.01 (+0.66%)

As of 06:17 PM Eastern

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Climb Bio NASDAQ:CLYM

$1.26 0.00 (0.00%)

As of 04:00 PM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Generation Bio NASDAQ:GBIO

$0.35 +0.02 (+6.94%)

Closing price 04:00 PM Eastern

Extended Trading

$0.36 +0.00 (+0.60%)

As of 07:49 PM Eastern

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Seres Therapeutics NASDAQ:MCRB

$11.60 +0.75 (+6.91%)

Closing price 04:00 PM Eastern

Extended Trading

$11.66 +0.06 (+0.56%)

As of 07:38 PM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time